Genomic analysis: Toward a new approach in breast cancer management

Critical Reviews in Oncology/Hematology

Volumn 81, Issue 3, 2012, Pages 207-223

  Cavallaro, Sebastiano ^a,b   Paratore, Sabrina ^a,b   de Snoo, Femke ^c   Salomone, Edvige ^b   Villari, Loredana ^b   Buscarino, Calogero ^b   Ferraù, Francesco ^b   Banna, Giuseppe ^b   Furci, Marco ^b   Strazzanti, Angela ^b   Cunsolo, Rosario ^b   Pezzino, Salvatore ^a,b   Gangi, Santi ^b   Basile, Francesco ^b  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Agendia NV   (Netherlands)

Author keywords

Breast cancer; Copy number variation; Expression profiling; Genomic assay; Personalized therapy; Prognosis

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GENOMIC DNA; MESSENGER RNA; PACLITAXEL; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

BACTERIAL ARTIFICIAL CHROMOSOME; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CHROMOSOME 10Q; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 16P; CHROMOSOME 16Q; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 22Q; CHROMOSOME 5Q; CHROMOSOME 6P; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLASSIFIER; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; COST EFFECTIVENESS ANALYSIS; DNA MICROARRAY; DRUG SENSITIVITY; ERBB2 GENE; GENE; GENE EXPRESSION PROFILING; GENE TECHNOLOGY; GENOME ANALYSIS; HIGH RISK PATIENT; HUMAN; INTRADUCTAL CARCINOMA; METHODOLOGY; MULTIPLE CYCLE TREATMENT; PROGNOSIS; REVIEW; SURVIVAL TIME;

BREAST NEOPLASMS; FEMALE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84856966747     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.03.006     Document Type: Review

References (134)

1. Morris S.R., Carey L.A. Molecular profiling in breast cancer. Rev Endocr Metab Disord 2007, 8:185-198.
2. Tan D.S., Lambros M.B., Natrajan R., Reis-Filho J.S. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007, 87:737-754.
3. Ylstra B., van den Ijssel P., Carvalho B., Brakenhoff R.H., Meijer G.A. BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res 2006, 34:445-450.
4. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95:14863-14868.
5. Hupe P., Stransky N., Thiery J.P., Radvanyi F., Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004, 20:3413-3422.
6. Shah S.P., Xuan X., DeLeeuw R.J., et al. Integrating copy number polymorphisms into array CGH analysis using a robust HMM. Bioinformatics 2006, 22:e431-e439.
7. Yang Y.H., Dudoit S., Luu P., et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002, 30:e15.
8. van Beers E.H., Nederlof P.M. Array-CGH and breast cancer. Breast Cancer Res 2006, 8:210.
9. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
10. Nishizaki T., Chew K., Chu L., et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 1997, 74:513-517.
11. Richard F., Pacyna-Gengelbach M., Schluns K., et al. Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 2000, 89:305-310.
12. Diallo R., Schaefer K.L., Bankfalvi A., et al. Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry. Hum Pathol 2003, 34:1299-1305.
13. Osin P., Lu Y.J., Stone J., et al. Distinct genetic and epigenetic changes in medullary breast cancer. Int J Surg Pathol 2003, 11:153-158.
14. Jones C., Foschini M.P., Chaggar R., et al. Comparative genomic hybridization analysis of myoepithelial carcinoma of the breast. Lab Invest 2000, 80:831-836.
15. Jones C., Nonni A.V., Fulford L., et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 2001, 85:422-427.
16. Aubele M.M., Cummings M.C., Mattis A.E., et al. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol 2000, 9:14-19.
17. Loveday R.L., Greenman J., Simcox D.L., et al. Genetic changes in breast cancer detected by comparative genomic hybridisation. Int J Cancer 2000, 86:494-500.
18. Loo L.W., Grove D.I., Williams E.M., et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004, 64:8541-8549.
19. Cingoz S., Altungoz O., Canda T., Saydam S., Aksakoglu G., Sakizli M. DNA copy number changes detected by comparative genomic hybridization and their association with clinicopathologic parameters in breast tumors. Cancer Genet Cytogenet 2003, 145:108-114.
20. Buerger H., Otterbach F., Simon R., et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 1999, 189:521-526.
21. Tanner M.M., Tirkkonen M., Kallioniemi A., et al. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1995, 1:1455-1461.
22. Muleris M., Almeida A., Gerbault-Seureau M., Malfoy B., Dutrillaux B. Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique. Genes Chromosomes Cancer 1994, 10:160-170.
23. Courjal F., Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res 1997, 57:4368-4377.
24. Isola J.J., Kallioniemi O.P., Chu L.W., et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 1995, 147:905-911.
25. Kallioniemi O.P., Kallioniemi A., Piper J., et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994, 10:231-243.
26. Kuukasjarvi T., Karhu R., Tanner M., et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997, 57:1597-1604.
27. Kuukasjarvi T., Tanner M., Pennanen S., Karhu R., Kallioniemi O.P., Isola J. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. Am J Pathol 1997, 150:1465-1471.
28. Ried T., Just K.E., Holtgreve-Grez H., et al. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res 1995, 55:5415-5423.
29. Allen J.J., Harmon-Jones E., Cavender J.H. Manipulation of frontal EEG asymmetry through biofeedback alters self-reported emotional responses and facial EMG. Psychophysiology 2001, 38:685-693.
30. Schwendel A., Richard F., Langreck H., et al. Chromosome alterations in breast carcinomas: frequent involvement of DNA losses including chromosomes 4q and 21q. Br J Cancer 1998, 78:806-811.
31. Tirkkonen M., Tanner M., Karhu R., Kallioniemi A., Isola J., Kallioniemi O.P. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998, 21:177-184.
32. Valladares A., Salamanca F., Madrigal-Bujaidar E., Arenas D. Identification of chromosomal changes with comparative genomic hybridization in sporadic breast cancer in Mexican women. Cancer Genet Cytogenet 2004, 152:163-166.
33. Gunther K., Merkelbach-Bruse S., Amo-Takyi B.K., Handt S., Schroder W., Tietze L. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001, 193:40-47.
34. Buerger H., Simon R., Schafer K.L., et al. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol 2000, 53:118-121.
35. Bae J.S., Choi J.S., Baik S.H., et al. Genomic alterations of primary tumor and blood in invasive ductal carcinoma of breast. World J Surg Oncol 2010, 8:32.
36. Washington C., Dalbegue F., Abreo F., Taubenberger J.K., Lichy J.H. Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas. Am J Pathol 2000, 157:323-329.
37. Waldman F.M., Hwang E.S., Etzell J., et al. Genomic alterations in tubular breast carcinomas. Hum Pathol 2001, 32:222-226.
38. Vincent-Salomon A., Gruel N., Lucchesi C., et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007, 9:R24.
39. Thor A.D., Eng C., Devries S., et al. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol 2002, 33:628-631.
40. Jones C., Ford E., Gillett C., et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004, 10:5988-5997.
41. Korsching E., Packeisen J., Agelopoulos K., et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002, 82:1525-1533.
42. Bergamaschi A., Kim Y.H., Wang P., et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006, 45:1033-1040.
43. Vincent-Salomon A., Lucchesi C., Gruel N., et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008, 14:1956-1965.
44. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
45. Selim A.G., Ryan A., El-Ayat G., Wells C.A. Loss of heterozygosity and allelic imbalance in apocrine metaplasia of the breast: microdissection microsatellite analysis. J Pathol 2002, 196:287-291.
46. Albertson D.G., Pinkel D Genomic microarrays in human genetic disease and cancer. Hum Mol Genet 2003, 12(Spec No. 2):R145-R152.
47. Robanus-Maandag E.C., Bosch C.A., Kristel P.M., et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 2003, 201:75-82.
48. Roylance R., Gorman P., Harris W., et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999, 59:1433-1436.
49. Cleton-Jansen A.M., Buerger H., Haar N., et al. Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 2004, 41:109-116.
50. Wessels L.F., van Welsem T., Hart A.A., van't Veer L.J., Reinders M.J., Nederlof P.M. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002, 62:7110-7117.
51. Joosse S.A., van Beers E.H., Tielen I.H., et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 2009, 116:479-489.
52. Rubinstein W.S. Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer 2008, 7:83-89.
53. Hedenfalk I., Ringner M., Ben-Dor A., et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci U S A 2003, 100:2532-2537.
54. Mangia A., Chiarappa P., Tommasi S., et al. Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers. Cancer Genet Cytogenet 2008, 182:75-83.
55. van Beers E.H., van Welsem T., Wessels L.F., et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005, 65:822-827.
56. Tirkkonen M., Johannsson O., Agnarsson B.A., et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997, 57:1222-1227.
57. Werner M., Mattis A., Aubele M., et al. 20q13.2 amplification in intraductal hyperplasia adjacent to in situ and invasive ductal carcinoma of the breast. Virchows Arch 1999, 435:469-472.
58. Gong G., DeVries S., Chew K.L., Cha I., Ljung B.M., Waldman F.M. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 2001, 7:2410-2414.
59. Boecker W., Buerger H., Schmitz K., et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol 2001, 195:415-421.
60. Jones C., Merrett S., Thomas V.A., Barker T.H., Lakhani S.R. Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast. J Pathol 2003, 199:152-156.
61. Mastracci T.L., Shadeo A., Colby S.M., et al. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast. Genes Chromosomes Cancer 2006, 45:1007-1017.
62. Simpson P.T., Reis-Filho J.S., Gale T., Lakhani S.R. Molecular evolution of breast cancer. J Pathol 2005, 205:248-254.
63. Moore E., Magee H., Coyne J., Gorey T., Dervan P.A. Widespread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast. Comparative genomic hybridization study of pure high-grade DCIS. J Pathol 1999, 187:403-409.
64. Mastracci T.L., Boulos F.I., Andrulis I.L., Lam W.L. Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer. Breast Cancer Res 2007, 9:215.
65. Nyante S.J., Devries S., Chen Y.Y., Hwang E.S. Array-based comparative genomic hybridization of ductal carcinoma in situ and synchronous invasive lobular cancer. Hum Pathol 2004, 35:759-763.
66. Yao J., Weremowicz S., Feng B., et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 2006, 66:4065-4078.
67. Amari M., Suzuki A., Moriya T., et al. LOH analyses of premalignant and malignant lesions of human breast: frequent LOH in 8p, 16q, and 17q in atypical ductal hyperplasia. Oncol Rep 1999, 6:1277-1280.
68. Reis-Filho J.S., Lakhani S.R. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res 2003, 5:313-319.
69. Etzell J.E., Devries S., Chew K., et al. Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol 2001, 32:292-296.
70. Lu Y.J., Osin P., Lakhani S.R., Di Palma S., Gusterson B.A., Shipley J.M. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 1998, 58:4721-4727.
71. Tran-Thanh D., Arneson N.C., Pintilie M., et al. Amplification of the prolactin receptor gene in mammary lobular neoplasia. Breast Cancer Res Treat 2010.
72. Aubele M., Auer G., Braselmann H., et al. Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal Cell Pathol 2002, 24:77-87.
73. Climent J., Martinez-Climent J.A., Blesa D., et al. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. Clin Cancer Res 2002, 8:3863-3869.
74. Dellas A., Torhorst J., Schultheiss E., Mihatsch M.J., Moch H. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer. Clin Cancer Res 2002, 8:1210-1216.
75. Fung L.F., Wong N., Tang N., et al. Genetic imbalances in pT2 breast cancers of southern Chinese women. Cancer Genet Cytogenet 2001, 124:56-61.
76. Hermsen M.A., Baak J.P., Meijer G.A., et al. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. J Pathol 1998, 186:356-362.
77. Hislop R.G., Pratt N., Stocks S.C., et al. Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer. Br J Surg 2002, 89:1581-1586.
78. Janssen E.A., Baak J.P., Guervos M.A., van Diest P.J., Jiwa M., Hermsen M.A. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 2003, 201:555-561.
79. Seute A., Sinn H.P., Schlenk R.F., et al. Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. Int J Cancer 2001, 93:80-84.
80. Weber-Mangal S., Sinn H.P., Popp S., et al. Breast cancer in young women (< or =35 years): genomic aberrations detected by comparative genomic hybridization. Int J Cancer 2003, 107:583-592.
81. Zudaire I., Odero M.D., Caballero C., et al. Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology 2002, 40:547-555.
82. Chin K., DeVries S., Fridlyand J., et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541.
83. Fridlyand J., Snijders A.M., Ylstra B., et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006, 6:96.
84. Hwang K.T., Han W., Cho J., et al. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Int J Cancer 2008, 123:1807-1815.
85. Li J., Gromov P., Gromova I., et al. Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis. Proteomics 2008, 8:5038-5052.
86. Climent J., Dimitrow P., Fridlyand J., et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res 2007, 67:818-826.
87. Karlsson E., Danielsson A., Delle U., Olsson B., Karlsson P., Helou K. Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer. Cancer Genet Cytogenet 2007, 172:139-146.
88. Han W., Han M.R., Kang J.J., et al. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 2006, 6:92.
89. Andre F., Job B., Dessen P., et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009, 15:441-451.
90. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
91. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423.
92. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
93. Kapp A.V., Jeffrey S.S., Langerod A., et al. Discovery and validation of breast cancer subtypes. BMC Genomics 2006, 7:231.
94. Sorlie T., Wang Y., Xiao C., et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127.
95. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003, 100:10393-10398.
96. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800.
97. Sotiriou C., Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007, 7:545-553.
98. Pusztai L. Chips to bedside: incorporation of microarray data into clinical practice. Clin Cancer Res 2006, 12:7209-7214.
99. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
100. Pusztai L., Cristofanilli M., Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin Oncol 2007, 34:S10-S16.
101. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007, 12:631-635.
102. Ross J.S., Hatzis C., Symmans W.F., Pusztai L., Hortobagyi G.N. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13:477-493.
103. de Snoo F., Bender R., Glas A., Rutgers E. Gene expression profiling: decoding breast cancer. Surg Oncol 2009, 18:366-378.
104. Folgueira M.A., Carraro D.M., Brentani H., et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005, 11:7434-7443.
105. Hannemann J., Oosterkamp H.M., Bosch C.A., et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005, 23:3331-3342.
106. Chang J.C., Wooten E.C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362:362-369.
107. Iwao-Koizumi K., Matoba R., Ueno N., et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23:422-431.
108. Bertucci F., Finetti P., Rougemont J., et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004, 64:8558-8565.
109. Jansen M.P., Foekens J.A., van Staveren I.L., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005, 23:732-740.
110. Ayers M., Symmans W.F., Stec J., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22:2284-2293.
111. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006, 24:4236-4244.
112. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
113. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272.
114. Liedtke C., Hatzis C., Symmans W.F., et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009, 27:3185-3191.
115. Oh D.S., Troester M.A., Usary J., et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006, 24:1656-1664.
116. Bild A.H., Yao G., Chang J.T., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357.
117. Potti A., Dressman H.K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12:1294-1300.
118. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
119. van de Vijver M.J., He Y.D., Van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
120. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98:1183-1192.
121. Bueno-de-Mesquita J.M., Linn S.C., Keijzer R., et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2008.
122. Mook S., Schmidt M.K., Viale G., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009, 116:295-302.
123. Mook S., Knauer M., Bueno-de-Mesquita J.M., et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010, 17:1406-1413.
124. Straver M.E., Glas A.M., Hannemann J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119:551-558.
125. Somlo G., Frankel P., Vora L., et al. Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin {+/-} trastuzumab in patients (pts) with stage II-III and inflammatory breast cancer (IBC). J Clin Oncol 2010, 540.
126. Knauer M., Mook S., Rutgers E.J., et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010, 120:655-661.
127. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
128. Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., Piccart-Gebhart M.J. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26:729-735.
129. Retel V.P., Joore M.A., Knauer M., Linn S.C., Hauptmann M., Harten W.H. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 2010, 46:1382-1391.
130. Thomassen M., Tan Q., Eiriksdottir F., Bak M., Cold S., Kruse T.A. Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer. Clin Cancer Res 2007, 13:5355-5360.
131. Haibe-Kains B., Desmedt C., Piette F., et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 2008, 9:394.
132. Haibe-Kains B., Desmedt C., Sotiriou C., Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?. Bioinformatics 2008, 24:2200-2208.
133. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569.
134. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65.